WASHINGTON — Sen. Bill Cassidy’s new perch as the top Republican on the Senate health committee has attracted some attention — and some campaign cash — from the executives of pharmaceutical companies, federal disclosures show.
The slew of campaign donations from drug industry executives came about a week after Cassidy, a Louisiana Republican, officially became the ranking member of the Senate health committee.
The contributions all came on either Feb. 10 or 11, and included $5,800 from Pfizer CEO Albert Bourla, $5,000 from Eli Lilly CEO David Ricks, $2,900 from Bristol Myers Squibb CEO Giovanni Caforio, and $2,500 from Biogen CEO Christopher Viehbacher, all of whom sit on PhRMA’s board.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect